Jane Street Group LLC grew its holdings in AnaptysBio Inc (NASDAQ:ANAB) by 133.2% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 8,842 shares of the biotechnology company’s stock after acquiring an additional 5,050 shares during the quarter. Jane Street Group LLC’s holdings in AnaptysBio were worth $920,000 as of its most recent SEC filing.
Other institutional investors have also made changes to their positions in the company. SG Americas Securities LLC bought a new stake in AnaptysBio during the first quarter worth about $173,000. Two Sigma Securities LLC bought a new stake in AnaptysBio during the fourth quarter worth about $212,000. Smith Asset Management Group LP bought a new stake in AnaptysBio during the first quarter worth about $243,000. Amalgamated Bank bought a new stake in AnaptysBio during the fourth quarter worth about $244,000. Finally, Raymond James Financial Services Advisors Inc. bought a new stake in AnaptysBio during the fourth quarter worth about $252,000.
Shares of NASDAQ ANAB opened at $71.04 on Friday. The company has a current ratio of 17.57, a quick ratio of 17.57 and a debt-to-equity ratio of 0.02. AnaptysBio Inc has a 12 month low of $20.12 and a 12 month high of $134.00.
AnaptysBio (NASDAQ:ANAB) last issued its earnings results on Tuesday, May 8th. The biotechnology company reported ($0.63) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.44) by ($0.19). During the same period in the previous year, the business earned ($0.75) earnings per share. equities research analysts forecast that AnaptysBio Inc will post -3.04 EPS for the current fiscal year.
Several research firms recently weighed in on ANAB. Royal Bank of Canada cut shares of AnaptysBio from an “outperform” rating to a “sector perform” rating and cut their price objective for the stock from $144.00 to $40.00 in a research report on Wednesday, April 4th. ValuEngine raised shares of AnaptysBio from a “hold” rating to a “buy” rating in a research report on Friday, June 1st. JMP Securities set a $180.00 price objective on shares of AnaptysBio and gave the stock a “buy” rating in a research report on Tuesday, March 27th. Stifel Nicolaus upped their price objective on shares of AnaptysBio from $130.00 to $139.00 and gave the stock a “buy” rating in a research report on Tuesday, March 6th. Finally, Zacks Investment Research cut shares of AnaptysBio from a “hold” rating to a “sell” rating in a research report on Friday, May 11th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the stock. AnaptysBio has a consensus rating of “Buy” and an average target price of $131.44.
In other AnaptysBio news, Director Nicholas Lydon sold 33,000 shares of the business’s stock in a transaction dated Monday, April 16th. The stock was sold at an average price of $86.88, for a total transaction of $2,867,040.00. Following the completion of the transaction, the director now owns 301,506 shares of the company’s stock, valued at $26,194,841.28. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 20.80% of the stock is currently owned by insiders.
AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's proprietary anti-inflammatory pipeline includes ANB020, an anti-interleukin-33 antibody for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy, and severe adult eosinophilic asthma; ANB019, an anti-interleukin-36R antibody for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases.
Want to see what other hedge funds are holding ANAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AnaptysBio Inc (NASDAQ:ANAB).
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.